136 related articles for article (PubMed ID: 32971585)
21. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
22. Upregulate KIF4A Enhances Proliferation, Invasion of Hepatocellular Carcinoma and Indicates poor prognosis Across Human Cancer Types.
Hou G; Dong C; Dong Z; Liu G; Xu H; Chen L; Liu L; Wang H; Zhou W
Sci Rep; 2017 Jun; 7(1):4148. PubMed ID: 28646197
[TBL] [Abstract][Full Text] [Related]
23. KIF4A knockdown suppresses ovarian cancer cell proliferation and induces apoptosis by downregulating BUB1 expression.
Jin W; Ye L
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34013367
[TBL] [Abstract][Full Text] [Related]
24. Integrative analysis of KIF4A, 9, 18A, and 23 and their clinical significance in low-grade glioma and glioblastoma.
Cho SY; Kim S; Kim G; Singh P; Kim DW
Sci Rep; 2019 Mar; 9(1):4599. PubMed ID: 30872592
[TBL] [Abstract][Full Text] [Related]
25. FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression.
Hu G; Yan Z; Zhang C; Cheng M; Yan Y; Wang Y; Deng L; Lu Q; Luo S
J Exp Clin Cancer Res; 2019 May; 38(1):188. PubMed ID: 31072351
[TBL] [Abstract][Full Text] [Related]
26. An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer.
Das R; Sjöström M; Shrestha R; Yogodzinski C; Egusa EA; Chesner LN; Chen WS; Chou J; Dang DK; Swinderman JT; Ge A; Hua JT; Kabir S; Quigley DA; Small EJ; Ashworth A; Feng FY; Gilbert LA
Nat Commun; 2021 Jul; 12(1):4601. PubMed ID: 34326322
[TBL] [Abstract][Full Text] [Related]
27. Large-Scale Transcriptome Data Analysis Identifies KIF2C as a Potential Therapeutic Target Associated With Immune Infiltration in Prostate Cancer.
Zhang P; Gao H; Ye C; Yan R; Yu L; Xia C; Yang D
Front Immunol; 2022; 13():905259. PubMed ID: 35720323
[TBL] [Abstract][Full Text] [Related]
28. Aberrant KIF20A Expression Is Associated with Adverse Clinical Outcome and Promotes Tumor Progression in Prostate Cancer.
Zhang Z; Chai C; Shen T; Li X; Ji J; Li C; Shang Z; Niu Y
Dis Markers; 2019; 2019():4782730. PubMed ID: 31565099
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer.
Li S; Wu Z; Chen Y; Kang Z; Wang H; He P; Zhang X; Hu T; Zhang Q; Cai Y; Xu X; Guan M
Tumour Biol; 2016 Apr; 37(4):5365-74. PubMed ID: 26561474
[TBL] [Abstract][Full Text] [Related]
30. RankProd Combined with Genetic Algorithm Optimized Artificial Neural Network Establishes a Diagnostic and Prognostic Prediction Model that Revealed C1QTNF3 as a Biomarker for Prostate Cancer.
Hou Q; Bing ZT; Hu C; Li MY; Yang KH; Mo Z; Xie XW; Liao JL; Lu Y; Horie S; Lou MW
EBioMedicine; 2018 Jun; 32():234-244. PubMed ID: 29861410
[TBL] [Abstract][Full Text] [Related]
31. Kinesin 12 (KIF15) contributes to the development and tumorigenicity of prostate cancer.
Qureshi Z; Ahmad M; Yang WX; Tan FQ
Biochem Biophys Res Commun; 2021 Oct; 576():7-14. PubMed ID: 34474246
[TBL] [Abstract][Full Text] [Related]
32. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
[TBL] [Abstract][Full Text] [Related]
33. Solute carrier family 16 member 5 downregulation and its methylation might serve as a prognostic indicator of prostate cancer.
Meng X; Yuan H; Li W; Xiong Z; Dong W; Xiao W; Zhang X
IUBMB Life; 2021 Nov; 73(11):1363-1377. PubMed ID: 34549875
[TBL] [Abstract][Full Text] [Related]
34. Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness.
Piao XM; Byun YJ; Jeong P; Ha YS; Yoo ES; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2017 Aug; 15(4):450-454. PubMed ID: 27842896
[TBL] [Abstract][Full Text] [Related]
35. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
36. KIF4A is a promising prognostic marker and correlates with immune infiltration in clear cell renal cell carcinoma.
Li C; Chen J; Su Z
Transl Cancer Res; 2020 Nov; 9(11):7165-7173. PubMed ID: 35117320
[TBL] [Abstract][Full Text] [Related]
37. Enhanced expression of KIF4A in osteosarcoma predicts a poor prognosis and facilitates tumor growth by activation of the MAPK pathway.
Zhu D; Xu X; Zhang M; Wang T
Exp Ther Med; 2021 Nov; 22(5):1339. PubMed ID: 34630693
[TBL] [Abstract][Full Text] [Related]
38. Early Stage Biomarkers Screening of Prostate Cancer Based on Weighted Gene Coexpression Network Analysis.
Meng L; Li Y; Ren J; Shi T; Men J; Chang C
DNA Cell Biol; 2019 May; 38(5):468-475. PubMed ID: 30835547
[TBL] [Abstract][Full Text] [Related]
39. KIF4A enhanced cell proliferation and migration via Hippo signaling and predicted a poor prognosis in esophageal squamous cell carcinoma.
Sun X; Chen P; Chen X; Yang W; Chen X; Zhou W; Huang D; Cheng Y
Thorac Cancer; 2021 Feb; 12(4):512-524. PubMed ID: 33350074
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancer.
Cui F; Hu J; Ning S; Tan J; Tang H
Prostate; 2018 Dec; 78(16):1299-1310. PubMed ID: 30095171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
